GlassScriptPhysician profile
Sandra M Corbin
NPI 1871585943
$3,500.66
in general payments reported to CMS, 2019-2025
21 companies · $943 in 2025
The $943 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $833 · 2022: $161 · 2023: $672 · 2024: $892 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $762.10 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $728.05 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $607.11 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $275.42 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $192.09 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $148.73 | 2021-2022 | |
| Strata Skin Sciences, INC. | $129.92 | 2025 | Xtrac |
| Janssen Biotech, INC. | $117.43 | 2021 | |
| Pfizer INC. | $115.12 | 2021-2023 | |
| Leo Pharma INC. | $87.92 | 2021-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.07 | 2023-2024 | Spevigo |
| Sun Pharmaceutical Industries INC. | $46.30 | 2021-2024 | |
| Vyne Pharmaceuticals INC. | $46.12 | 2021 | |
| Lilly USA, LLC | $33.10 | 2021 | |
| Krystal Biotech INC | $30.27 | 2024 | Vyjuvek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $28.42 | 2021-2023 | Valchlor |
| Sanofi-Aventis U.S. LLC | $24.52 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.11 | 2023 | Ycanth |
| Organogenesis INC. | $17.17 | 2023 | Puraply |
| Galderma Laboratories, L.P. | $13.39 | 2021 | |
| Dermavant Sciences, INC. | $13.30 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.